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To determine the effect of chemoprophylaxis on the
case-fatality rate of malaria, we analyzed all cases of
Plasmodium falciparum malaria in nonimmune persons
reported from 1993 to 2004 in Germany. In univariate and
multivariate logistic regression analysis, we determined the
effect of age, sex, chemoprophylaxis, chemoprophylactic
regimen, compliance for chemoprophylactic regimen,
exposure prophylaxis, country of infection, and year of
reporting on the outcome. Of 3,935 case-patients, 116 (3%)
died of malaria. Univariate analysis showed significant
associations with death for chemoprophylaxis with chloro-
quine plus proguanil compared to no chemoprophylaxis.
The multivariate model showed that patients who had taken
chemoprophylaxis were less likely to die compared to those
who had not taken chemoprophylaxis, adjusted for patient
age and reporting year. The study demonstrated that
chemoprophylaxis significantly reduced fatality rates
among nonimmune malaria patients and supports the
importance of existing guidelines for malaria prevention.
T
he estimated risk of nonimmune travelers to malaria-
endemic countries acquiring malaria is 1–357 per
100,000 depending on endemicity of the country (1).
Approximately 800 imported malaria cases are reported
through the notifiable disease surveillance system in
Germany each year, about twice as many per population as
in the United States (2). Within the World Health
Organization European Region, Germany is the country
with the third largest number of reported imported malaria
cases following France and the United Kingdom (3).
Exposure prophylaxis (repellents and bed nets) and
chemoprophylaxis are established methods of preventing
malaria during travel in malaria-endemic countries; its
importance has recently been underlined by Chen and
Keystone as well as by Zuckerman (4,5). Persons from
nonendemic countries are considered nonimmune because
their risk of acquiring malaria and subsequently develop-
ing severe disease with possible fatal outcome is consider-
ably higher than for adults who have spent their childhood
in a malaria-endemic environment (6).
The lack of randomized controlled trials on the effec-
tiveness of chemoprophylaxis on appropriately character-
ized travelers has been rightly criticized, yet the
methodologic difficulties of realizing such investigations
are obvious (7). Alternative study designs based on sur-
veillance data may provide some evidence whether non-
immune travelers to malaria-endemic countries would
have benefited from chemoprophylaxis even if it had
failed to prevent the disease. The strongest outcome meas-
ure for this question is the case-fatality ratio (CFR).
Because fatal malaria is rare in nonendemic countries,
various studies on imported malaria have not had the sta-
tistical power to investigate the case-fatality rate under
inclusion of relevant confounders (8,9). Multinational net-
works able to overcome the problem of small sample size
collect their data from specialized centers, causing a num-
ber of selection biases that may have particular impact on
the CFR (8,10).
Methods
From 1993 to 2000, physicians and laboratories in
Germany reported malaria cases to local health depart-
ments, which then sent special case report forms to the
Robert Koch Institute, the federal agency for infectious
disease control. The forms contain information on age,
sex, travel history, Plasmodium species, prophylactic
measures, onset of disease, and death. Since 2001, after
new legal requirements, laboratories and physicians report
directly to the Robert Koch Institute. The report forms
have had only minor changes over the years, which
ensures comparability of the data.
The study was limited to reported Plasmodium falci-
parum malaria in persons from nonendemic countries. A
case of P. falciparum malaria was determined when P. fal-
ciparum was directly detected in a person’s blood. All
cases of mixed infections containing P. falciparum and
another subspecies were removed from the analysis. 
Endemicity of a country was determined by using the
World Health Organization’s list of malaria-endemic coun-
tries (11). Only persons with German nationality or origin
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*Robert Koch-Institute, Berlin, Germanyor cases originating from other nonendemic countries were
considered nonimmune and included in the study. Country
of infection was defined as the malaria-endemic country in
which the patient stayed during the incubation period. If
>1 country was named, the region or continent to which all
countries belong was used.
Death was used as the outcome variable. The following
confounding variables were considered for the analysis:
age, sex, year of reporting, chemoprophylaxis, chemopro-
phylactic regimen, patient compliance for chemoprophy-
laxis, exposure prophylaxis (repellents and bed nets), and
country of infection. All but the first 3 variables were
assessed by patient history. Information on type of treat-
ment and time between onset of symptoms and treatment
was not included in the analysis as it was not consistently
available throughout the study period.
For univariate and multivariate logistic regression
analysis, we used SPSS version 13.0 (SPPS Inc., Chicago,
IL, USA). The method for variable selection was forward
stepwise (using likelihood ratio statistics) taking into
account all variables listed in Table 1. The confidence
interval (CI) for all analysis was 95%. 
Results
From 1993 to 2004, the Robert Koch Institute received
reports on 6,964 cases of P. falciparum malaria, 2,371
cases due to other species or mixed infections, and 521
cases due to unidentified species. Among the cases of P.
falciparum malaria, 3,935 (57%) patients were nonim-
mune and included in the subsequent analysis. A total of
116 patients in this study population died, resulting in a
CFR of 3% (Table 2). Chemoprophylaxis was taken by
1,581 (42%) of the 3,752 persons for whom this informa-
tion was available. The proportion of persons who took
chemoprophylaxis declined over the years (Figure).
Univariate analysis of risk factors is shown in Table 1.
Variables not shown in these tables were not significantly
associated with death in any of the analyses.
Univariate analysis showed that increasing age and
infection acquired in Africa were positively associated
with fatal outcome. Chloroquine plus proguanil was
inversely associated with fatal outcome compared to no
chemoprophylaxis. The year of reporting was significantly
associated with fatal outcome but did not show a linear
association.
The results of multivariate analysis are shown in Table 3.
In contrast to the univariate analysis, chemoprophylaxis
was significantly associated with death. Age and reporting
year remained significantly associated in the multivariate
model (Table 3). 
Discussion
This study demonstrated an independent effect of
chemoprophylaxis on fatal outcome. For nonimmune
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chemoprophylaxis (adjusted for age and reporting year),
the risk of dying of the disease was two thirds that of those
who had not taken any chemoprophylaxis (odds ratio [OR]
0.63, 95% CI 0.40–0.98). We are not aware of any such
association being reported. Yet the findings are consistent
with earlier reports (9,12). Our findings are also in line
with observations made in numerous case reviews in
which severity of illness appeared to be lower among
patients who had taken chemoprophylaxis compared to
patients who had not (13–15). Fatal outcome could be seen
as the consequence of severe malaria, which in turn is
associated with high parasitemia (9,13). If unable to pre-
vent infection, chemoprophylaxis would likely slow down
the parasite growth rate, which would result in a larger
window of opportunity in which treatment might prevent
death (14,16). Our data suggest that even in cases where
chemoprophylaxis fails to prevent the development of
malaria, it still significantly reduces the risk of dying from
it. This finding may be important for travelers to malaria-
endemic countries, adding another good reason to take
chemoprophylaxis, in addition to reducing the risk of
acquiring the disease.
Our study was also able to individually analyze specif-
ic chemoprophylactic regimens and identify significant
associations for some of the individual regimens. In the
univariate analysis, the risk of dying from malaria for
patients who had taken the combination of chloroquine
plus proguanil as a chemoprophylaxis regimen was less
than one third that of those patients who had not taken any
chemoprophylaxis (OR 0.28, 95% CI 0.10–0.77).
Chemoprophylaxis with doxycycline, atovaquone/
proguanil, mefloquine, or proguanil did not show a signif-
icant association. This finding may be because the smaller
prevalence of these regimens may have resulted in insuffi-
cient statistical power and does not necessarily question
the prophylactic effectiveness of these regimens (7). 
We can assume that recommendations for chemopro-
phylaxis were quite similar at any given point in time, since
our study population was limited to Germany, and they
agree with the current recommendations in the United
States and the United Kingdom (5,17–21). The risk for
infection, particularly the prevalence of chloroquine-resist-
ant  P. falciparum, has changed over the years in some
endemic regions, and our study design has partly controlled
for this by including the reporting year into the model. 
The analysis also showed that increasing age was an
independent risk factor for death. Age has been identified
as a risk factor for severe disease or fatal outcome of
malaria in several studies and case reports from the United
States, Europe, and Israel (8,9,12,15,16,22,23). In contrast
to those previous studies, we decided not to group the age
into categories because our study population was suffi-
ciently large to use age as a continuous variable, which
allowed us to avoid any kind of classification bias. Our
findings confirmed that the risk of dying from malaria
increases with age (OR 1.06, 95% CI 1.04–1.07). As dis-
cussed by Mühlberger et al., the most likely explanation
for the observed age effect is that with increasing age the
immune system looses its capacity to generate a competent
immune response against previously unencountered
pathogens (12). Our study adds an important conclusion to
this finding: although the elderly have an increased risk of
dying from malaria, they can significantly reduce this risk
by taking chemoprophylaxis. 
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Figure. Proportional frequency of chemo-
prophylactic regimen taken by nonimmune
patients with imported Plasmodium falci-
parum malaria, Germany, 1993–2004.The reporting year proved to be significantly associat-
ed with the CFR. We controlled for it by including it in the
model as a categoric variable, since the association was not
a linear one. We recommend that controlling for the year of
data collection should also be considered in similar analy-
ses of data collected over an extended period of time. 
Although a technical change in the reporting mecha-
nism occurred in 2001, it is not likely associated with the
observed change of CFR; the decline in CFR was already
observed before 2001, and the national death registry also
showed a parallel decline of malaria deaths (24). From
1989 to 1995, CFR for all cases has generally been higher
in Germany (3.6%) than in several other European coun-
tries and the United States (≈1%) (25). Meanwhile, CFR in
Germany has declined to <1%. This decline may have
been caused by a combination of better prophylactic regi-
mens, improved pretravel counseling, chemoprophylaxis
compliance, and earlier diagnosis and treatment. The treat-
ment delay and type of treatment, in particular, might have
played a role. Although this information was not consis-
tently available in the study population, reporting forms
have been changed so that future analyses should provide
some evidence for or against this hypothesis. Additionally,
physicians and pharmacies have begun providing pretrav-
el advice, which may have affected the aforementioned
factors. Providing this advice in the past has been the
domain of a few highly specialized centers (26). 
The study was focused on nonimmune patients, which
were identified by their nationality or citizenship (until
reporting year 2000) or by country of origin (from report-
ing year 2001 onwards). Both variables serve as a proxy
for non-immunity and have been used as such in previous
studies (12,15). During a transition period from 1999 to
2000, nationality and country of birth were simultaneous-
ly assessed in our surveillance system, and a comparison
of both variables showed that the discrepancy was ≈5%.
Therefore, we do not expect this technical change to have
any relevant impact on our findings. Legal constraints do
not allow collecting information on ethnicity or more
detailed information on the geographic origin of a person
in Germany.
In contrast to studies based on single institutions or net-
works of specialized centers, our study population is rep-
resentative in that it included cases identified by any labo-
ratory regardless of where and how the patient was treated.
This strategy reduces the risk for selection bias, which is of
particular importance when studying CFR. 
The univariate analysis indicates that malaria acquired
in Africa has a higher CFR than malaria acquired else-
where (10,13). Lewis et al. have shown that severe malar-
ia was observed more commonly in patients returning from
countries in central, southern, and eastern Africa compared
to those returning from countries in western Africa (15).
However, risk assessment with reference to the country of
infection is problematic, as reliable denominator data on
exposure are difficult to obtain, often do not take the dura-
tion of exposure into account, and may not be reliable
(25,27–30).
While chemoprophylaxis clearly reduces the risk of
acquiring malaria in nonimmune persons, the travelers’
compliance in taking chemoprophylaxis is quite variable
(3,30–32). Depending on the country and the method of
assessment, the proportion of malaria patients who take
chemoprophylaxis is 19%–90% and has repeatedly been
identified as a major limitation of preventing imported
malaria (2,4,14,33,34). Like the recent publication by
Askling et al. (1), this work demonstrates how data origi-
nating from notifiable disease surveillance may lead to
research results with important clinical implications, there-
fore underlining the importance of such surveillance sys-
tems. We demonstrated that chemoprophylaxis signifi-
cantly increases the chance of nonimmune patients to sur-
vive imported P. falciparum malaria. We suggest that this
information be used in pretravel counseling to further
motivate persons traveling in malaria-endemic countries to
comply with recommended chemoprophylactic regimens.
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